Camille Locht: An innovative solution to infant whooping cough

January 15, 2014

Scientists involved in the EU-funded project ChildInnovac are about to publish in the online journal Plos One the results of their first clinical trial of a new nasal vaccine. Designed for infants, it targets whooping cough, a common and, sometimes deadly, infant illness. Camille Locht, a researcher at the Infection and Immunity Centre of the Lille Pasteur Institute, in France, is also the project coordinator. He tells about the advantages of the new approach, developed as part of the project, to counter the current upsurge in the number of cases of whooping cough—a disease also known as pertussis. But there is still a long way ahead before this new vaccine enters the market.

Why test a new vaccine against whooping cough, when a vaccine already exists?

The World Health Organisation has noticed a global upsurge in cases. This disease now accounts for 20 to 40 million cases and for about 200,000 casualties per year across the world. In the USA, the highest number of cases in 60 years was recorded in 2012, with more than 48,000 cases. There is a similar trend in the UK, the Netherlands, Germany, Japan and Australia... This upsurge is attributed to a limited long-term efficacy of the traditional vaccine delivered during childhood. As a result, teenagers and adults catch whooping cough and infect infants, who are much more sensitive to the disease.

What are the advantages of the new nasal vaccine?

The whooping cough bacteria used to make this vaccine is live but attenuated. When it is inhaled, it colonises the upper , in the same way that the natural bacteria would do, and triggers a local immune response. This approach is specifically designed for infants. Indeed, their immune system is not mature enough to effectively respond to traditional vaccination by injection.

What are the results of the first clinical trial?

We tested the vaccine on an adult cohort of 48 people in the end of 2010. We have demonstrated that our vaccine has no noticeable side effects. Furthermore, we have an estimation of the right dose to use for the bacteria to colonise the respiratory tract and induce an .

What is the next step?

The next steps will consist in finding a new formulation of the vaccine in order to make it more stable. Indeed, it is now preserved at minus 80 °C but should ultimately be kept at ambient temperature.

Also, we have to fine-tune the right dose to inhale. All these steps will be achieved in partnership with the pharmaceutical industry. For this purpose, the Lille Pasteur Institute and the technology transfer arm of the French National Institute of Health and Medical Research (Inserm) , Inserm Transfert , have signed scientific collaboration and worldwide license agreements with a US-based biotechnology company, called Iliad biotechnologies, and based in Wilmington, Delaware.

When is this vaccine likely to be available on the market ?

Not before ten years at best! Indeed, there will be several steps before we can test it on infants. There will be new with the stabilised version of the , due to be tested first on adults and, possibly, on teenagers. We are currently in discussions with national health agencies around the world to set up such trials.

Explore further: Successful test in humans of a nasal vaccine against pertussis

Related Stories

Successful test in humans of a nasal vaccine against pertussis

January 9, 2014
The CHILD-INNOVAC European research programme, coordinated by Inserm, has enabled the development of an innovative vaccine that can be administered intranasally, to combat pertussis, which has shown a resurgence in developed ...

Whooping cough shot cuts illness, maybe not spread

November 25, 2013
A government study offers a new theory on why the whooping cough vaccine doesn't seem to be working as well as expected.

Whooping cough vaccine antigen disappearing from bacteria in US

December 12, 2013
Vaccines for whooping cough contain three to five protective antigens, the presence of which are critical to the vaccine's effectiveness. But one of the antigens, pertactin, which had been present in almost all isolates of ...

2012 was worst year for whooping cough since 1955

January 4, 2013
Health officials say 2012 was the nation's worst year for whooping cough in nearly six decades.

Panel: All adults should get whooping cough shots

February 22, 2012
A federal advisory panel wants all U.S. adults to get vaccinated against whooping cough.

New whooping cough strain in US raises questions

February 6, 2013
Researchers have discovered the first U.S. cases of whooping cough caused by a germ that may be resistant to the vaccine.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.